Kornimate/medical-research-clean huggingface dataset:
photobiomodulation in palate wounds: somatosensorial evaluation

Conditions: Surgical Wound

Summary: the goal of this clinical trial is to compare the effects of photobiomodulation with red laser on gingival graft donor areas of the palate in comparison to only protection with wound dressing. the main questions it aims to answer are: does photobiomodulation on the palate promote faster somatosensory recovery? does photobiomodulation reduce pain in palate donor sites, improving the quality of life? participants who need gingival graft surgeries will receive laser irradiation on the palate donor area or just protection with wound dressing. data will be collected up to 60 days. researchers will compare protection on the palate and protection plus laser irradiation to see if laser therapy may reduce pain and accelerate somatosensory normalization. moreover, they will measure changes in the quality of life after treatment.


Eligibility criteria:
inclusion criteria: * palate with normal and healthy mucosa * patient with indication of gingival graft surgery exclusion criteria: * patients using prosthesis with palate coverage * former removal of gingival graft in the palate * smokers * pregnancy and breastfeeding mothers * use of anticonvulsants and immunosuppressors
thrombosis and covid-19

Conditions: Thrombosis; Covid-19; SARS-CoV 2

Summary: the coronavirus disease of 2019 (covid-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (sars-cov2), now deemed a pandemic by the world health organization. some covid-19 patients may develop coagulopathy which is associated with poor prognosis and high risk of thrombosis. some patients develop severe thrombotic complications, such as pulmonary embolism, despite anti-thrombotic prophylaxis by low molecular weight heparin. the aim of this project is to evaluate modified thromboelastometry for identifying patients at high risk of thrombosis. the hypothesize is that hypofibrinolysis with increased plasma pai-1, tafi (thrombin-activatable fibrinolysis inhibitor ) levels in association with high thrombin generation may explain high incidence of thrombosis in this population. a simple laboratory assay, widely available in hospitals, such as thromboelastometry, might be of great clinical interest to detect covid-19 patients with high risk of thrombosis. in order to make rotem more sensitive to hypofibrinolysis, exogenous t-pa will be added in the assay. the preliminary results showed that patients with covid-19 have significant hypercoagulability detectable with rotem and covid-19 patients with thrombosis have both hypercoagulability and hypofibrinolysis.


Eligibility criteria:
inclusion criteria: * patients with covid-19 * non-opposition of the patient to participate exclusion criteria: * non-covid-19 acute respiratory distress syndrome * non-covid septicemia * pregnant women * breastfeeding women * protected vulnerable adults
role of fibirnogen like protein 2 as aprognostic factor in high grade glioma

Conditions: Brain Tumor Adult

Summary: the study population was selected from high grade glioma pateints attending the department of clinical oncology, assiut university hospital during the period from december 2018 to september 2020, we analyzed human high grade gliomas paraffin block for flg2 expression

glioblastoma is the most common malignant primary brain tumor in adults, and despite aggressive treatment, it is incurable patient prognosis differs considerably within the different world health organization (who) grades, poorest prognosis for patients with the grade iv tumour- the glioblastoma multiform (gbm). fibrinogen-like protein 2 (fgl2),regulates both innate and adaptive immunity. fgl2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen. secreted fgl2 (sfgl2) is the key regulator in immunosuppression may play important role in malignant transformation of low to high by inhibiting the proliferation of t cell study the role of fibrinogen-like protein2 on immunosuppression and progression ，free survival and overall survival in high grade glioma

Eligibility criteria:
inclusion criteria: * pateints\>18 years old * pathologically proven high grade glioma * total or subtotal resection of the tumor * patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months exclusion criteria: * pregnancy * breast feeding * other comorbidity * previous malignancy or radiation therapy or chemotherapy
the coexistence of atherosclerotic intracranial arterial stenosis with intracranial aneurysms

Conditions: Atherosclerotic Intracranial Arterial Stenosis With Intracranial Aneurysms

Summary: atherosclerotic intracranial arterial（ica） stenosis and intracranial aneurysms are the common causes of ischemic stroke and hemorrhagic stroke, respectively. investigators aimed to assess the prevalence of cerebral aneurysms in patients with atherosclerotic intracranial arterial stenosis.

based on prospective data of patients with symptomatic or asymptomatic ica stenosis admitted to beijing tiantan hospital between jan 2015 and july 2016, all patients underwent brain cta / mra/dsa. investigators determined the number of the patients with intracranial aneurysms, calculated overall prevalence of the coexistence of atherosclerotic ica stenosis with aneurysms and analyzed the clinical features.

Eligibility criteria:
inclusion criteria: 1. dsa identified the coexistence of intracranial arterial stenosis with intracranial aneurysms 2. stenosis caused by atherosclerosis exclusion criteria: 1. patients do not agree 2. stenosis caused by no atherosclerosis disease

Keywords: atherosclerotic intracranial arterial stenosis intracranial aneurysms
a randomized double-blind placebo-controlled study to evaluate the effects of a dietary supplement on children's health and development outcomes.

Conditions: Height and Weight; Cognitive Function

Summary: a 6-month virtual two-armed randomized double-blind placebo-controlled clinical trial. participants will take nubest tall growth protein powder or a placebo daily. parents will complete questionnaires at baseline and monthly, and children will undergo cognitive assessments and height/weight measurements at specified intervals.


Eligibility criteria:
inclusion criteria: * interested in their child trialing a dietary supplement designed to improve overall health outcomes in children including height, maintenance of a healthy weight, cognitive function, immune function, and energy levels. * willing to refrain from giving their child any vitamins, minerals, or herbal supplements of any kind for the duration of the study. * parents willing to weigh and measure the height of their child throughout the study. * generally healthy - do not have any uncontrolled chronic disease. exclusion criteria: * any child with a history of endocrine disorder, heart disease, lung disease, kidney disease, digestive disease, or skeletal dysplasia. * any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * is undergoing or planning to undergo significant medical procedures in the next six months. * a history of severe allergic reactions, including but not limited to any of the product's ingredients. * any child with a dairy allergy or lactose intolerance. * has undergone any surgeries or invasive treatments in the last six months. * has had any major illness in the last three months. * having any planned invasive medical procedures during the study period. * currently participating in any other clinical study. * unwilling to follow the study protocol. * any child diagnosed with attention-deficit disorder (add) or attention-deficit hyperactivity disorder (adhd). * any child currently taking or have taken in the last 3 months any prescription medication targeting add or adhd (such as adderall, concerta, focalin, evekeo, or ritalin). * any child that is a 'fussy' eater or who the parent suspects may not tolerate consuming the test product daily for six months.

Keywords: dietary supplement growth and development
eus-guided transmural drainage of walled-off pancreatic necrosis: plastic vs metallic protesis.

Conditions: Pancreas Necrosis; Pancreatic Collection

Summary: randomized multicenter study comparing plastic stents and self-expanding metallic stents in the eus-guided transmural drainage of walled-off pancreatic necrosis. spanish centers partners of the spanish society of digestive endoscopy.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * patient with indication (asge, jacobson bc, gie2005;) of pancreatic collection drainage type walled-off pancreatic necrosis \* as a local complication of previous acute pancreatitis. * patient trained to understand and / or sign informed consent * patient who understands the type of study and will comply with all follow-up of complementary tests during its duration exclusion criteria: * pregnancy or breastfeeding * severe coagulation disorder: inr\> 1.5 not correctable with plasma and / or platelet administration \<50,000 / mm3 * asymptomatic patients, with no clinical indication of drainage, except for those with vascular involvement due to compression (eg stenosis, splenic vessels with collateral circulation, and risk of bleeding) * non-identification of solid content during the endoscopic ultrasound of the procedure * no informed consent * in the case of patients with mental retardation, without the ability to understand the nature and possible consequences of the study, except for the existence of a legal representative * patients unable to maintain posterior follow-up (lack of adherence) * situations that do not allow the practice of a high digestive endoscopy (eg, stenosis)

Keywords: pancreas endoscopic intervention plastic stent self expanding metallic stent endoscopic transmural drainage walled off pancreatic necrosis
prospective study of particle radiotherapy for breast cancer with different arm position

Conditions: Breast Cancer

Summary: the optical body surface image (c-rad) was used to guide and track the change of positions, and multimodal images (including 2d x-ray images, ct images and pet-ct images) were used to verify the treatment positions. in order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images. in a word, this is a dosimetry and prospective phase ii randomized clinical study of the accuracy of multi-modal guided particle radiotherapy for postoperative breast cancer with different arm position.

pet-ct: positron emission tomography - computed tomography ct: computed tomography

Eligibility criteria:
inclusion criteria: 1. patients with pathologically (cytological or histological) confirmed breast cancer with positive lymph nodes and postoperative adjuvant radiotherapy 2. exclude distant metastasis 3. no ipsilateral breast and breast radiation therapy 4. exclude patients requiring axillary irradiation 5. age 18-80 years old 6. general good health (eastern cooperative oncology group, ecog 0-2) 7. no complications such as severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, or severe chronic heart disease that may affect radiotherapy. 8. non-pregnant (confirmed by serum or urine β-hcg test) or lactating women 9. patients must sign informed consent to receive radiotherapy. exclusion criteria: 1. pathology unapproved breast cancer 2. with distant metastasis 3. the ipsilateral breast or breast has received radiation therapy 4. patients requiring axillary irradiation 5. the dose limit of organs at risk cannot reach the preset safe dose limit 6. pregnancy (confirmed by serum or urine β-hcg test) or lactation 7. poor general health, karnofsky performance status (kps)\ 2 8. severe complications that may affect radiotherapy, including: a) unstable angina pectoris, congestive heart failure, myocardial infarction requiring hospitalization in the past 6 months, b) acute bacterial or systemic fungal infection, c) hospitalization for exacerbations of chronic obstructive pulmonary disease (copd) or other respiratory diseases 9. unable to understand the purpose of treatment or unwilling to sign the treatment consent

Keywords: immobilization positions breast cancer particle radiotherapy dosimetry multi-modal guided radiotherapy
individual treatment of ustekinumab in perianal fistulizing crohn's disease

Conditions: Crohn Disease

Summary: this study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula crohn's disease.

participants in the study receive ustekinumab injections as part of routine medical care. the study just observes the efficacy retrospectively and does not interfere with treatment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of perianal fistulizing crohn's disease * receive ustekinumab therapy exclusion criteria: * ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs * combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, graves disease, etc. * combined with serious infectious diseases, such as active tuberculosis, ebv infection, cytomegalovirus infection, etc. * combined with malignant tumor * clinical data missing ≥30% or no follow-up
clinical diagnosis of diabetes using surface-enhanced raman spectroscopy liquid biopsy and machine learning

Conditions: Diabetes

Summary: this project aims to adapt the gold nanoparticle-based surface-enhanced raman spectroscopy (sers) technology to clinical application. in this exploratory study, a measurement protocol will be established to investigate whether sers (combined with multivariate data analysis or machine learning algorithms) allows the diagnosis of patients with diabetes.

this study on the clinical application of surface-enhanced raman spectroscopy (sers) comprises two parts. first, a sers measurement protocol will be developed to enhance the interactions between gold nanoparticles and the components of the patient's samples, maximizing raman spectroscopical signatures. given the complex composition of human blood, which encompasses numerous biological constituents, the study focuses on serum, a component obtained through centrifugation after removing cells and clotting factors. fifteen spectra will be recorded per sample. the raw spectra will be post-processed, including removal of the substrate signal, baseline correction, vector normalization, and smoothing steps. the sers measurement protocol established in the first section will subsequently be applied to samples of healthy and diabetes patients. two different approaches will be followed. first, multivariate data analysis will be performed to identify distinctive feature characteristics in the samples that correlate to their group (healthy and diabetes patients), allowing patient diagnosis. second, different machine learning algorithms and data augmentation strategies will be explored for better patient diagnosis.

Eligibility criteria:
inclusion criteria: * patient at nishtar medical university * patient age from 18 to 70 years * confirmed disease (for diabetic group) exclusion criteria: * patients with severe concurrent diseases

Keywords: diabetes sensing sers gold nanoparticles diagnositcs surface-enhanced raman spectroscopy
effects of ulnar styloid and sigmoid notch fractures on postoperative wrist function of distal radius fracture patients

Conditions: Radius Fracture Distal

Summary: to study the effects of ulnar styloid and sigmoid notch fractures on postoperative wrist function in patients with distal radius fracture

patients treated for distal radius fracture in the department of orthopedic trauma at the people's hospital of peking university will be selected for outpatient follow-up. evaluation was based on sartiento's modification of the gartland and werley score. efficacy was assessed with wrist pain as the focus.the follow-up time is one year after the operation。

Eligibility criteria:
inclusion criteria: 1. unilateral distal radius fracture with or without ulnar styloid fracture, closed fracture 2. distal radius fracture repaired by internal fixation using a palmar plate 3. age of ≥18 years 4. integral clinical data, a postoperative follow-up period of ≥12 months 5. distal radius fracture with normal union 6. provision of informed consent after receiving an explanation of the purpose of this study exclusion criteria: 1. old fracture, pathological fracture, open fracture 2. bilateral distal radius fracture 3. fracture of other parts of the wrist (excluding the ulnar styloid)

Keywords: distal radius fracture, sigmoid notch
observational study to evaluate long-term outcome in hip hemiarthroplasty

Conditions: Hip Fractures; Hip Hemiarthroplasty; Osteoarthritis, Hip; Avascular Necrosis of Hip; Femoral Neck Fractures

Summary: this pmcf study is designed to collect safety and efficacy data on hip hemiarthroplasty surgeries with corin bipolar-i shell and the oceane+ or meije duo femoral stem up to 10 years.

as part of the current clinical remediation work under the new medical device regulation (mdr), limited data have been identified to support the hemiarthroplasty indication for some of corin femoral stems. therefore, this pmcf study has been implemented to collect safety and performance data on hip hemiarthroplasty surgeries with corin bipolar-i shell and the oceane+ or meije duo femoral stem up to 10 years.

Eligibility criteria:
inclusion criteria: 1. both genders. 2. adult subjects. 3. subjects clinically suitable for a hip hemiarthroplasty surgery with corin hip devices based on physical examination, medical history and diagnosis such as: non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis in which the acetabulum does not require replacement, treatment of non-union, femoral neck and trochanteric fractures of the proximal femur, revision of failed partial hip replacements in which the acetabulum does not require replacement. 4. the subject is willing to comply with the required follow-up visits as per protocol. 5. the subject has signed a patient informed consent form (picf), specific to this study, and approved by the local ec. exclusion criteria: 1. subjects with active infection or sepsis or osteomyelitis. 2. subjects with unsuitable or insufficient bone support preventing proper fixation of the prosthesis. 3. subject with marked bone loss or bone absorption. 4. subject with metabolic disorders which may impair bone formation or bone quality. 5. subjects under guardianship. 6. subjects in the opinion of the investigator/ investigative team who will be unable to comply with study procedures (examples: recent psychotic or mania disorders, alcohol, drug or substance abusers) and/or those unable for any medical or other reason to comply with study procedures/visits.

Keywords: hemiarthroplasty acetabulum hip fractures
a two-arm (phase 2) exploratory study of nivolumab monotherapy or in combination with nab-paclitaxel and carboplatin in early stage nsclc in china

Conditions: Non Small Cell Lung Cancer

Summary: nivolumab (bms-936558) is a fully human, igg4 (kappa) isotype mab that binds pd-1 on activated immune cells and disrupts engagement of the receptor with its ligands pd-l1 (b7 h1/cd274) and pd-l2 (b7-dc/cd273), thereby abrogating inhibitory signals and augmenting the host antitumor response. in early clinical trials, nivolumab has demonstrated activity in several tumor types, including melanoma, renal cell carcinoma (rcc), and non-small cell lung cancer (nsclc). nivolumab is in clinical development for the treatment of patients with nsclc, rcc, melanoma, squamous cell carcinoma of the head and neck (scchn) and other tumors (eg, glioblastoma multiforme, mesothelioma, small cell lung cancer, gastric). nivolumab is approved in the united states (us), european union, and other countries for the treatment of patients with unresectable or metastatic melanoma, advanced nsclc with progression on or after platinum-based chemotherapy, advanced rcc whose disease progressed on an antiangiogenic therapy, classical hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin treatment, and recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. the proposed study will evaluate the efficacy and safety of preoperative administration of nivolumab or nivolumab combined with nab-paclitaxel and carboplatin in neoadjuvant setting and administration of nivolumab in adjuvant setting in patients with high-risk resectable nsclc, and will facilitate a comprehensive exploratory characterization of the tumor immune microenvironment and circulating immune cells in these patients. data obtained in this study will provide valuable information for planning further prospective clinical trials of anti-pd-1 and other immunotherapies in nsclc, both in the peri-operative and advanced disease setting. ultimately, it is highly desirable to discover prospective biomarkers of response and toxicity to allow patients with nsclc who are most likely to derive benefit to receive anti-pd-1 treatment, and conversely to minimize the risk of toxicity and ineffective treatment for patients who are unlikely to benefit.


Eligibility criteria:
inclusion criteria: * early stage ib-iiia, operable non-small cell lung cancer, confirmed in tissue * lung function capacity capable of tolerating the proposed lung surgery * eastern cooperative oncology group (ecog) performance status of 0-1 * available tissue of primary lung tumor exclusion criteria: * presence of locally advanced, inoperable or metastatic disease * participants with active, known or suspected autoimmune disease * prior treatment with any drug that targets t cell co-stimulations pathways (such as checkpoint inhibitors) other protocol defined inclusion/exclusion criteria could apply
detection of early lung cancer by serum protein expression profiling

Conditions: Non-small Cell Lung Cancer

Summary: promising new technology exists to examine small proteins that are shed by cancers into the blood stream. the purpose of this study is to see if there are differences in the proteins and protein levels in blood from individuals with early stage lung cancer compared to healthy adults.

a prospective longitudinal patient-based pilot study is proposed whereby surfaced enhanced laser desorption ionization time-of-flight mass spectroscopy (seldi-tof-ms) will be used to discover and validate serum proteomic expression profiles diagnostic of early lung cancer. a unique approach will be used to compare the serum proteomic expression profiles of patients with non-small cell lung cancer compared to healthy heavy smoking adults, as well as differences before and after anatomic pulmonary resection with curative intent. discriminatory proteins will be selected by their differential expression before compared to after surgical removal of a tumor. the protein profile of blood obtained from the draining pulmonary vein at the time of resection will be used to identify materials potentially shed by the tumor that may serve as biomarkers in peripheral blood. the serum samples will be used to develop a training data set and then a test set for validation using a class prediction model. candidate proteomic patterns will then serve as a basis for a larger prospective multi-centre clinical trial.

Eligibility criteria:
inclusion criteria: * presence of early stage non-small cell lung cancer * elective surgical resection of lung lesion at vancouver general hospital (vgh) * no preoperative chemoradiation therapy * no previous cancer * ability to provide informed consent

Keywords: early stage (0/i) non-small cell lung cancer